An Adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine

K. Kiura; T. Ohnoshi; H. Ueoka; N. Takigawa; M. Tabata; Y. Segawa; T. Shibayama; I. Kimura

An Adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine

K. Kiura, T. Ohnoshi, H. Ueoka, N. Takigawa, M. Tabata, Y. Segawa, T. Shibayama, I. Kimura

University Hospital

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Lonidamine, a unique new type of anticancer agent has been shown to exert marginal activity in patients with resistant small cell lung cancer. We have assessed cytotoxic activity using seven human small cell lung cancer cell lines and the drug resistant small cell lung cancer sublines, Adriamycin-resistant SBC-3/ ADM100, etoposide-resistant SBC-3/ETP and cisplatin-resistant SBC-3/CDDP. Although lonidamine had only a minimal activity in seven human small cell lung cancer cell lines, SBC-3/ADM100 cells were more sensitive to lonidamine than the parent SBC-3 cells to a 1.6-fold extent in terms of IC₅₀. SBC-3/CDDP and SBC-3/ ETP had no cross-resistance to lonidamine at all. These observations may be of potential clinical significance in treating small cell lung cancer.

Original language	English
Pages (from-to)	463-470
Number of pages	8
Journal	Anti-Cancer Drug Design
Volume	7
Issue number	6
Publication status	Published - Dec 1 1992

ASJC Scopus subject areas

Biochemistry
Oncology
Biochemistry, Genetics and Molecular Biology(all)
Pharmacology
Drug Discovery
Organic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{8c5d66da9e834283b99f84bdcfb7ca5b,

title = "An Adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine",

abstract = "Lonidamine, a unique new type of anticancer agent has been shown to exert marginal activity in patients with resistant small cell lung cancer. We have assessed cytotoxic activity using seven human small cell lung cancer cell lines and the drug resistant small cell lung cancer sublines, Adriamycin-resistant SBC-3/ ADM100, etoposide-resistant SBC-3/ETP and cisplatin-resistant SBC-3/CDDP. Although lonidamine had only a minimal activity in seven human small cell lung cancer cell lines, SBC-3/ADM100 cells were more sensitive to lonidamine than the parent SBC-3 cells to a 1.6-fold extent in terms of IC50. SBC-3/CDDP and SBC-3/ ETP had no cross-resistance to lonidamine at all. These observations may be of potential clinical significance in treating small cell lung cancer.",

author = "K. Kiura and T. Ohnoshi and H. Ueoka and N. Takigawa and M. Tabata and Y. Segawa and T. Shibayama and I. Kimura",

year = "1992",

month = dec,

day = "1",

language = "English",

volume = "7",

pages = "463--470",

journal = "Anti-Cancer Drug Design",

issn = "0266-9536",

publisher = "Cognizant Communication Corporation",

number = "6",

}

TY - JOUR

T1 - An Adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine

AU - Kiura, K.

AU - Ohnoshi, T.

AU - Ueoka, H.

AU - Takigawa, N.

AU - Tabata, M.

AU - Segawa, Y.

AU - Shibayama, T.

AU - Kimura, I.

PY - 1992/12/1

Y1 - 1992/12/1

N2 - Lonidamine, a unique new type of anticancer agent has been shown to exert marginal activity in patients with resistant small cell lung cancer. We have assessed cytotoxic activity using seven human small cell lung cancer cell lines and the drug resistant small cell lung cancer sublines, Adriamycin-resistant SBC-3/ ADM100, etoposide-resistant SBC-3/ETP and cisplatin-resistant SBC-3/CDDP. Although lonidamine had only a minimal activity in seven human small cell lung cancer cell lines, SBC-3/ADM100 cells were more sensitive to lonidamine than the parent SBC-3 cells to a 1.6-fold extent in terms of IC50. SBC-3/CDDP and SBC-3/ ETP had no cross-resistance to lonidamine at all. These observations may be of potential clinical significance in treating small cell lung cancer.

AB - Lonidamine, a unique new type of anticancer agent has been shown to exert marginal activity in patients with resistant small cell lung cancer. We have assessed cytotoxic activity using seven human small cell lung cancer cell lines and the drug resistant small cell lung cancer sublines, Adriamycin-resistant SBC-3/ ADM100, etoposide-resistant SBC-3/ETP and cisplatin-resistant SBC-3/CDDP. Although lonidamine had only a minimal activity in seven human small cell lung cancer cell lines, SBC-3/ADM100 cells were more sensitive to lonidamine than the parent SBC-3 cells to a 1.6-fold extent in terms of IC50. SBC-3/CDDP and SBC-3/ ETP had no cross-resistance to lonidamine at all. These observations may be of potential clinical significance in treating small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027103922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027103922&partnerID=8YFLogxK

M3 - Article

C2 - 1337430

AN - SCOPUS:0027103922

SN - 0266-9536

VL - 7

SP - 463

EP - 470

JO - Anti-Cancer Drug Design

JF - Anti-Cancer Drug Design

IS - 6

ER -

An Adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this